Roche jumps on the data transparency bandwagon; Quintiles spent big leading up to IPO;

> Following GlaxoSmithKline's ($GSK) lead, Roche ($RHHBY) has agreed to give researchers access to anonymized clinical trial data for all its approved products. Article

> In the 16 months leading up to its IPO filing, Quintiles spent more than $280 million on acquisitions to boost its presence in the CRO world. Story

> Pharma Tech Industries has signed on to provide filling, assembly and packaging for OptiNose's nasally delivered migraine treatment. News

> Xceleron is partnering with consulting outfit Kinetigen to offer simple, robust Phase I clinical investigations to its clients. More

> CMO Althea Technologies has inked a deal with Profectus BioSciences to manufacture the company's DNA vaccines. Item

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.